Twist Bioscience (NASDAQ:TWST) CFO Sells $189,116.25 in Stock

Key Points

• Twist Bioscience CFO Adam Laponis sold 5,875 shares of stock for a total of $189,116.25, reducing his ownership by 5.71%. He still owns approximately 97,042 shares valued at over $3.1 million.
• Despite a recent earnings report that beat analyst expectations, Twist Bioscience continues to face negative net margins and a challenging stock price, with a current trading price of $32.79.
• Analysts have mixed ratings on Twist Bioscience, with price targets ranging from $40.00 to $48.50, reflecting a consensus of "Moderate Buy" from nine analysts.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 5,875 shares of the stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $32.19, for a total transaction of $189,116.25. Following the completion of the sale, the chief financial officer directly owned 97,042 shares in the company, valued at approximately $3,123,781.98. The trade was a 5.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock traded up $1.67 on Wednesday, reaching $32.79. The stock had a trading volume of 2,438,969 shares, compared to its average volume of 1,273,207. Twist Bioscience Corporation has a 1 year low of $24.07 and a 1 year high of $55.33. The company has a market cap of $1.98 billion, a P/E ratio of -22.61 and a beta of 2.38. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The business's 50 day moving average is $27.76 and its two-hundred day moving average is $32.84.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The firm had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

TWST has been the topic of several research reports. Barclays decreased their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating on the stock in a research note on Thursday, October 2nd. Evercore ISI decreased their price target on shares of Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating on the stock in a research note on Tuesday. Cowen reissued a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a research note on Wednesday. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Twist Bioscience presently has an average rating of "Moderate Buy" and an average price target of $48.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock worth $85,000 after purchasing an additional 302 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after purchasing an additional 303 shares during the last quarter. D.A. Davidson & CO. grew its holdings in shares of Twist Bioscience by 1.5% in the second quarter. D.A. Davidson & CO. now owns 23,062 shares of the company's stock worth $848,000 after purchasing an additional 352 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Twist Bioscience by 0.8% in the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company's stock valued at $1,994,000 after acquiring an additional 442 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its holdings in Twist Bioscience by 8.4% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company's stock valued at $222,000 after acquiring an additional 469 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.